SFS
SNDX icon

Sowell Financial Services’s Syndax Pharmaceuticals SNDX Stock Holding History

Sowell Financial Services’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-69,748
Closed -$1.47M – 788
2023
Q1 		$1.47M Buy
+69,748
New +$1.74M 0.11% 218

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Sowell Financial Services's SNDX Position: Q2 2023 in Review

Sowell Financial Services sold out of Syndax Pharmaceuticals (SNDX) in Q2 2023, closing a stake of 69,748 shares — an estimated $1.47M sold.

Sowell Financial Services first reported a position in SNDX in Q1 2023 and held it in 1 quarter. The position peaked at $1.47M in Q1 2023. 166 funds tracked by Wall St. Rank hold SNDX as of Q2 2023.

  • Sowell Financial Services reported no remaining Syndax Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Sowell Financial Services sold 69,748 Syndax Pharmaceuticals shares in Q2 2023, an estimated $1.47M.
  • Sowell Financial Services first reported a position in Syndax Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Sowell Financial Services's Syndax Pharmaceuticals position peaked at $1.47M in Q1 2023.
  • 166 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2023.

Based on Sowell Financial Services's 13F filing for Q2 2023, filed 14 Aug 2023.